Dear colleagues and friends,
I am privileged to invite you to the 2nd Extracellular Matrix Pharmacology Congress (ECM2024) on 17-19 June 2024 in beautiful Copenhagen, Denmark.
Dysregulation of the extracellular matrix (ECM), characterized by either elevated degradation or formation of tissues, is a universal characteristic observed in many chronic diseases. To make a real impact on the lives of patients, we need to learn from other diseases where fibrosis and tissue destruction are also central mechanisms involved in the pathophysiology.
After numerous years of ECM research, it became clear to me that we need a forum to bring leading experts across borders and generations together to discuss how to modulate the ECM in different disease areas. Thus, the idea for the ECM Pharmacology Congress was born.
ECM2022 was a great success with more than 400 participants from 30 countries, 200 high-quality abstracts, and 40 speakers – all with one goal: improving our understanding of the ECM across different diseases. Moreover, ECM2022 gave rise to a series of virtual symposiums which further advance our understanding of these critical subjects.
At ECM2024, we aim to repeat the success and offer an unforgettable mix of networking and state-of-the-art research. The program will include internationally renowned ECM researchers, practitioners, and industry experts from different disease areas: liver, lung, kidney, cardiovascular, metabolic, cancer (tumor fibrosis), skin, and immunology, in which the central common denominator is changes to the ECM.
The central theme of ECM2024 will revolve around target discovery and drug development, intending to cross-fertilize and assist drug development. The center of it all will be ECM pharmacology and how its modulation can help patients.
I hope that ECM2024 will be a successful and enlightening event for all those who attend, and I look forward to welcoming you to the 2nd ECM Pharmacology Congress!
We hope to see you at ECM2024.
Morten Karsdal, PhD, Professor